You are here

Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy.

Last updated on August 9, 2018

FOR MORE INFORMATION
Study Location
Instituto de Oncologia de Rosario
Rosario, Santa FE, S2000KZE Argentina
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neoplasm Metastasis, Musculoskeletal Pain
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Personally signed and dated informed consent document.

- Willing and able to comply with scheduled visits, treatment plan, laboratory tests,
and other study procedures.

- Male or female, ≥18 years of age

- Weight ≥40 kg at Screening

- Cancer diagnosed as having metastasized to bone or multiple myeloma.

- Imaging confirmation of bone metastasis at Screening or within 120 days prior to the
Screening visit.

- Expected to require daily opioid medication throughout the course of the study.

- Willing to not use prohibited medications (including NSAIDs) throughout the duration
of the study.

- Average Pain Score ≥5 at Screening for the index bone metastasis cancer pain site.

- Patient's Global Assessment of Cancer Pain of "fair", "poor" or "very poor" at
Screening.

- Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0, 1, or 2 at
Screening.

- Adequate bone marrow, renal and liver function at Screening.

- International Normalized Ratio (INR) or prothrombin time (PT) unless being treated with anticoagulant medication.

- Females must either be not of childbearing potential or, if of childbearing potential
and at risk for pregnancy, must be willing to use at least one highly effective method
of contraception throughout the study and for 112 days (16 weeks) after the last dose
of assigned subcutaneous study medication.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Pain related to an oncologic emergency.

- Brain metastasis or leptomeningeal metastasis.

- Presence of hypercalcemia at Screening.

- Pain primarily classified as not predominantly related to a bone metastasis.

- Systemic treatment for the primary malignancy or bone metastasis started within 30
days of the Baseline Assessment Period.

- Chemotherapies associated with peripheral neuropathy (ie, paclitaxel, docetaxel,
oxaliplatin, cisplatin, vincristine, thalidomide or bortezomib) are prohibited during
study period from 30 days prior to the first day of the Baseline Assessment Period to
Week 32.

- Receipt of radiopharmaceutical treatment or radiotherapy for treatment of bone
metastasis within 30 days of the Baseline Assessment Period.

- Concurrent adjuvant analgesics unless started at least 30 days prior to the start of
the Baseline Assessment Period and maintained at a stable dose.

- Diagnosis of osteoarthritis of the knee or hip or findings consistent with
osteoarthritis in the shoulder.

- History of significant trauma or surgery to a major joint within one year prior to
Screening.

- History of osteonecrosis or osteoporotic fracture.

- X-ray evidence at Screening of: 1) rapidly progressive osteoarthritis, 2) atrophic or
hypotrophic osteoarthritis, 3) subchondral insufficiency fracture, 4) spontaneous
osteonecrosis of the knee (SPONK), 5) osteonecrosis, or 6) pathologic fracture.

- Signs and symptoms of clinically significant cardiac disease.

- Evidence of orthostatic hypotension at Screening or at Baseline prior to
randomization.

- Diagnosis of a transient ischemic attack in the 6 months prior to Screening or
diagnosis of stroke with significant residual deficits.

- History, diagnosis, or signs and symptoms of clinically significant neurological
disease.

- Total impact score of >7 on the Survey of Autonomic Symptoms (SAS) at Screening.

- Past history of carpal tunnel syndrome (CTS) with signs or symptoms of CTS in the one
year prior to Screening.

- History of significant alcohol, analgesic, or narcotic substance abuse within the six
months prior to Screening.

- Planned surgical procedure during the duration of the study.

- Considered unfit for surgery or not willing to undergo joint replacement surgery if
required.

- Known hypersensitivity to opioids or an underlying medical condition contraindicating
opioid use.

- History of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal
antibody or IgG-fusion protein.

- Previous exposure to exogenous nerve growth factor or to an anti-nerve growth factor
antibody.

- Presence of drugs of abuse, prescription medications without a valid prescription or
other illegal drugs at Screening.

- Positive Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus (HIV) tests at
Screening indicative of current infection.

- Investigational site staff members and their family members, or Pfizer employees
directly involved in the conduct of the trial.

- Participation in other studies involving investigational drug(s) within 30 days (or 90
days for investigational biologics) before Baseline Assessment Period and/or during
study participation.

- Pregnant female subjects; breastfeeding female subjects; female subjects of
childbearing potential who are unwilling or unable to use one (1) highly effective
method of contraception throughout the study and for 112 days after last dose of
investigational product.

- Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality.

NCT02609828
Pfizer
Recruiting
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Sickle Cell Anemia, Sickle Cell Disease, Sickle Cell Disorders, Pain Crisis, Vaso-occlusive Crisis
NCT02433158
All Genders
6+
Years
Multiple Sites
Breast Neoplasms, Stomach Neoplasms, Esophagogastric Junction Neoplasm, Non-small-cell Lung Carcinoma
NCT03284723
All Genders
18+
Years
Multiple Sites
Pain
NCT01266161
All Genders
16+
Years
Multiple Sites
Breast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
NCT01945775
All Genders
18+
Years
Multiple Sites
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy.
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of The Subcutaneous Administration Of Tanezumab (Pf-04383119) In Subjects With Cancer Pain Predominantly Due To Bone Metastasis Receiving Background Opioid Therapy
The purpose of this study is to determine whether tanezumab is effective in the treatment of cancer pain due to bone metastasis in patients already taking background opioid therapy.

This is a randomized, double-blind, placebo-controlled, multicenter, parallel-group Phase 3 study in cancer subjects requiring treatment with background opioids for pain due to bone metastasis.

Approximately 170 subjects will be randomized to one of 2 treatment groups in a 1:1 ratio (approximately 85 subjects per group). Subjects will receive a total of 3 subcutaneous injections, separated by 8 weeks in addition to background opioids administered throughout the study.

Treatment groups will include: 1. Placebo SC (matching tanezumab SC) in addition to background opioid therapy. 2. Tanezumab 20 mg SC in addition to background opioid therapy.

The study consists of three periods: Pre-Treatment (up to 37 days), Double-Blind Treatment (24 weeks) and Safety Follow-up (24 weeks).

Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Neoplasm Metastasis
  • Musculoskeletal Pain
Drug: Tanezumab
Subcutaneous study treatment (tanezumab 20 mg or matched placebo) dosed at 8 week intervals.
Other Name: PF-04383119
  • Experimental: Arm 1
    Tanezumab 20 mg subcutaneously
    Intervention: Drug: Tanezumab
  • Placebo Comparator: Arm 2
    Placebo matched to active treatment subcutaneously
    Intervention: Drug: Tanezumab
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
255
July 21, 2020
September 29, 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Personally signed and dated informed consent document.
  • Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  • Male or female, ?18 years of age
  • Weight ?40 kg at Screening
  • Cancer diagnosed as having metastasized to bone or multiple myeloma.
  • Imaging confirmation of bone metastasis at Screening or within 120 days prior to the Screening visit.
  • Expected to require daily opioid medication throughout the course of the study.
  • Willing to not use prohibited medications (including NSAIDs) throughout the duration of the study.
  • Average Pain Score ?5 at Screening for the index bone metastasis cancer pain site.
  • Patient's Global Assessment of Cancer Pain of "fair", "poor" or "very poor" at Screening.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0, 1, or 2 at Screening.
  • Adequate bone marrow, renal and liver function at Screening.
  • International Normalized Ratio (INR) or prothrombin time (PT) <1.5 x ULN at Screening unless being treated with anticoagulant medication.
  • Females must either be not of childbearing potential or, if of childbearing potential and at risk for pregnancy, must be willing to use at least one highly effective method of contraception throughout the study and for 112 days (16 weeks) after the last dose of assigned subcutaneous study medication.

Exclusion Criteria:

  • Pain related to an oncologic emergency.
  • Brain metastasis or leptomeningeal metastasis.
  • Presence of hypercalcemia at Screening.
  • Pain primarily classified as not predominantly related to a bone metastasis.
  • Systemic treatment for the primary malignancy or bone metastasis started within 30 days of the Baseline Assessment Period.
  • In Japan only, chemotherapies associated with peripheral neuropathy (ie, paclitaxel, docetaxel, oxaliplatin, cisplatin, vincristine, thalidomide or bortezomib) are prohibited during study period from 30 days prior to the first day of the Baseline Assessment Period to Week 32.
  • Receipt of radiopharmaceutical treatment or radiotherapy for treatment of bone metastasis within 30 days of the Baseline Assessment Period.
  • Concurrent adjuvant analgesics unless started at least 30 days prior to the start of the Baseline Assessment Period and maintained at a stable dose.
  • Diagnosis of osteoarthritis of the knee or hip or findings consistent with osteoarthritis in the shoulder.
  • History of significant trauma or surgery to a major joint within one year prior to Screening.
  • History of osteonecrosis or osteoporotic fracture.
  • X-ray evidence at Screening of: 1) rapidly progressive osteoarthritis, 2) atrophic or hypotrophic osteoarthritis, 3) subchondral insufficiency fracture, 4) spontaneous osteonecrosis of the knee (SPONK), 5) osteonecrosis, or 6) pathologic fracture.
  • Signs and symptoms of clinically significant cardiac disease.
  • Evidence of orthostatic hypotension at Screening or at Baseline prior to randomization.
  • Diagnosis of a transient ischemic attack in the 6 months prior to Screening or diagnosis of stroke with significant residual deficits.
  • History, diagnosis, or signs and symptoms of clinically significant neurological disease.
  • Total impact score of >7 on the Survey of Autonomic Symptoms (SAS) at Screening.
  • Past history of carpal tunnel syndrome (CTS) with signs or symptoms of CTS in the one year prior to Screening.
  • History of significant alcohol, analgesic, or narcotic substance abuse within the six months prior to Screening.
  • Planned surgical procedure during the duration of the study.
  • Considered unfit for surgery or not willing to undergo joint replacement surgery if required.
  • Known hypersensitivity to opioids or an underlying medical condition contraindicating opioid use.
  • History of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal antibody or IgG-fusion protein.
  • Previous exposure to exogenous nerve growth factor or to an anti-nerve growth factor antibody.
  • Presence of drugs of abuse, prescription medications without a valid prescription or other illegal drugs at Screening.
  • Positive Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus (HIV) tests at Screening indicative of current infection.
  • Investigational site staff members and their family members, or Pfizer employees directly involved in the conduct of the trial.
  • Participation in other studies involving investigational drug(s) within 30 days (or 90 days for investigational biologics) before Baseline Assessment Period and/or during study participation.
  • Pregnant female subjects; breastfeeding female subjects; female subjects of childbearing potential who are unwilling or unable to use one (1) highly effective method of contraception throughout the study and for 112 days after last dose of investigational product.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
Argentina,   Australia,   Austria,   Brazil,   Chile,   China,   Czechia,   France,   Germany,   Hungary,   Israel,   Japan,   Korea, Republic of,   Poland,   Romania,   Slovakia,   Spain,   United Kingdom
Czech Republic
 
NCT02609828
A4091061
2013-002223-42 ( EudraCT Number )
CANCER PAIN PH 3 SC STUDY ( Other Identifier: Alias Study Number )
Yes
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Pfizer
Pfizer
Eli Lilly and Company
Study Director: Pfizer CT.gov Call Center Pfizer
Principal Investigator: Christos Karapetis, MD Flinders cancer innovation centre, Flinders Medical Centre
Principal Investigator: Patricia Milhomem, MD Centro de Pesquisas Clinicas da Fundação Hospital Amaral Carvalho
Principal Investigator: Fernanda Damian, MD União Brasileira de Educação e Assintência Hospital Sao Lucas DA PUCRS
Principal Investigator: Rudolf Likar, MD Dep. of Anesthesiology and Intensiv Care Medicine, Klinikum Klagenfurt
Principal Investigator: Ludmila Koch, MD Hospital Israelita Albert Einstein
Principal Investigator: Felipe Cruz, MD IBCC - Instituto Brasileiro de Controle do Câncer
Principal Investigator: Sandra Serrano, MD Fundacao Antonio Prudente - Hospital A.C. Camargo/Hospital do Cancer
Principal Investigator: Martin Smakal, MD Oncology department of Nemocnice Benesov
Principal Investigator: Jiri Klecka, MD Research Site Ltd
Principal Investigator: Petra Panovcova, MD Nemocnice Horovice
Principal Investigator: Ondrej Slama, MD Masarykuv onkologicky ustav, Klinika komplexni onkologicke pece
Principal Investigator: Zbigniew Nowecki, MD MSCM Cancer Center and Institute Oncology
Principal Investigator: Viliam Cibik, MD Slovak Research Center
Principal Investigator: Lubomira Nemcikova, MD Neurology and pain out patient clinic/NCI
Principal Investigator: Keon Uk Park, MD Department of Oncology/Keimyung University Dongsan Medical Center
Principal Investigator: Joo Hyuk Sohn, MD Severance Hospital
Principal Investigator: Marie Fallon, MD Edinburgh Cancer Research Centre (IGMM)
Principal Investigator: Peter Barrett-Lee, MD Velindre Cancer Centre
Principal Investigator: Alejandro Orts Castro, MD Hospital Sanitas La Moraleja
Principal Investigator: Lee Na Teo, MD Ballarat Health Services
Principal Investigator: Giuliano Borges, MD Clinica de Neuoplasias Litoral - Centro de Novos Tratamentos Itajaí
Principal Investigator: Tiago Biachi de Castria, MD Instituto do Cancer do Estado de Sao Paulo
Principal Investigator: Jung Hye Kwon, MD Hallym University Kangdong Sacred Heart Hospital
Principal Investigator: Pavol Demo, MD Ambulancia Klinickej onkologie FNsP Nove Zamky
Principal Investigator: Jitka Fricova, MD General University Hospital
Principal Investigator: Georg Nuhr, MD Nuhr Medical Center
Principal Investigator: Patricia Santi, MD Faculdade de Medicina do ABC/CEPHO - Centro de Estudos e Pesquisa em Hematologia e Oncologia
Principal Investigator: Susanne Costa, MD Instituto Nacional de Câncer - INCA
Principal Investigator: Philippe Poulain, MD Polyclinique de L'ormeau
Principal Investigator: Andrzej Stachowiak, MD Pallmed Sp. z o.o. NZOZ Dom Sue Ryder
Principal Investigator: Maciej Sopata, MD Poradnia Medycyny Paliatywnej Hospicjum Palium
Principal Investigator: Carlos Jara Sanchez, MD Hospital Universitario Fundacion de Alcorcon
Principal Investigator: Maria Salete Nascimento, MD Hospital do Cancer de Barretos Fundacao Pio XII
Principal Investigator: Tatiana Pietrzynska, MD Powiatowy Zespo Zakadow Opieki Zdrowotnej w Bdzinie, Oddzia Opieki Paliatywnej Szpital Czelad
Principal Investigator: Agnieszka Kluczna, MD Niepliczny Zakad Opieki Zdrowotnej Zespo Medyczno-Opieku-Czy Alicja Kluczna
Principal Investigator: Ancor Serrano Afonso, MD L'Hospitalet de Llobregat
Principal Investigator: Michael Franco, MD Monash Medical Centre - Moorabin Campus
Principal Investigator: Magdalena Korozan, MD Hospicjum im. Ks. Eugeniusza Dutkiewicza SAC w Gdansku
Principal Investigator: Marcin Janecki, MD Stowarzyszenie Przyjacio Chorych Hospicjum w Gliwicach NZOZ Hospicjum Miosierdzia Boego
Principal Investigator: Hedviga Jakubikova, MD Sanera, s.r.o. Neurologicka a algeziologicka ambulancia
Principal Investigator: César Margarit Ferri, MD Hospital General Universitario Dd Alicante
Principal Investigator: Tae-Yong Kim, MD Department of Oncology/ Seoul National University Hospital
Principal Investigator: Concepción Pérez Hernández, MD Hospital Universitario La Princesa
Principal Investigator: Dirk Forstmeyer, MD Universitätsklinikum Leipzig AöR Universitäres Krebszentrum Leipzig (UCCL)
Principal Investigator: Tibor Csoszi, MD Hetenyi G Korhaz
Principal Investigator: Laszlo Landherr, MD Uzsoki utcai Kórház
Principal Investigator: Andras Telekes, MD Bajcsy-Zsilinszy Hospital
Principal Investigator: Roxana Ioana Scheusan, MD Oncocenter Onclogie Clinica S.R.L
Principal Investigator: Dan Lungulescu, MD SC Oncolab SRL
Principal Investigator: Carmen Crihana, MD Department of Oncology at CF Clinical Hospital
Principal Investigator: Burkhard Gustorff, MD Wilhelminenspital der Stadt Wien
Principal Investigator: Zsofia Polya, MD Josa András Teaching Hospital
Principal Investigator: Jinsoo Chung, MD National Cancer Center
Principal Investigator: Michael Schenker, MD SF Nectarie Oncology Centre
Principal Investigator: Maria Goretti Pazos Gonzalez, MD Complexo Hospitalario Universitario A Coruna
Principal Investigator: Han Yong Choi, MD Samsung Medical Center
Principal Investigator: Raúl Sala, MD Instituto de Oncologia de Rosario
Principal Investigator: Juan Cúndom, MD Fundacion Favaloro Para La Docencia e Investigacion Medica
Principal Investigator: Medgyasszay Balazs, MD Veszprém Megyei Tüd?gyógyintézet Farkasgyep?
Principal Investigator: Tamás Pintér, MD Petz Aladár Country Teaching Hospital Gyor
Principal Investigator: Thomas Cuvier, MD Departmental Hosptital of Vendee
Principal Investigator: Lynn Maeda, MD Nishinomiya Municipal Central Hospital
Pfizer
November 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now